Cargando…
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer
PURPOSE: Adjuvant FOLFOX therapy is an established standard-of-care for resected colon cancer. Peripheral sensory neuropathy (PSN) is regarded as the major toxicity issue related to FOLFOX therapy. There have been a few reports on the recovery status from PSN thereafter. JOIN trial investigated the...
Autores principales: | Yoshino, Takayuki, Kotaka, Masahito, Shinozaki, Katsunori, Touyama, Tetsuo, Manaka, Dai, Matsui, Takanori, Ishigure, Kiyoshi, Hasegawa, Junichi, Inoue, Keiji, Munemoto, Yoshinori, Takagane, Akinori, Ishikawa, Hiroshi, Ishida, Hideyuki, Ogata, Yutaka, Oba, Koji, Goto, Koichi, Sakamoto, Junichi, Maehara, Yoshihiko, Ohtsu, Atsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820589/ https://www.ncbi.nlm.nih.gov/pubmed/31549217 http://dx.doi.org/10.1007/s00280-019-03957-5 |
Ejemplares similares
-
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015) -
Poor association between dihydropyrimidine dehydrogenase (
DPYD
) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022) -
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
por: Kotaka, Masahito, et al.
Publicado: (2018) -
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial
por: Yoshino, Takayuki, et al.
Publicado: (2019) -
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)